PharmTech Drug Digest 11.20
News|Articles|July 26, 2013

New Manufacturing Method Improves Drug Delivery of Asthma Inhalers

Australian team develops method for making ultrafine particles for more efficient drug delivery.

A chemical engineering team from Monash University in Australia developed a method to manufacture ultrafine particles that will improve the consistency and efficiency of drugs used in metered-dose inhalers to treat asthma, the University announced in a press release. The anti-solvent vapor precipitation method uses ethanol to dehydrate droplets, which results in ultrafine particles with a more uniform size.

 “Ultrafine uniform particles will ensure that fewer drug particles get stuck in the throat while more can reach the lower regions of the lungs,” said team leader Dr. Meng Wai Woo. “Because we can now make the small particles more uniform, it means the inhalers will work better. From a drug manufacturer’s perspective, this new approach can maintain the uniformity of the particle and yet potentially maintain commercially viable production rates.”

The team’s work results in particles smaller than a micron in diameter. These particles are much smaller than those produced by conventional dehydrating mechanisms, which are limited by the size of the atomized droplet.

Assisted by a grant from the Australian Research Council, the Monash team is now testing its method on whey to research the ultrafine particle delivery of protein-based medicines. The team is also building a demonstration unit, which will be completed later this year, to showcase the anti-solvent vapor precipitation process.


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.